Allegra Asthma Claim Would Be Key Defense Vs. Forced OTC Switch – Aventis
This article was originally published in The Tan Sheet
Executive Summary
Aventis' Allegra experimental asthma indication would be the best defense against a forced OTC switch of the antihistamine, Chief Operating Officer Richard Markham told analysts during Aventis' R&D day in London June 18
You may also be interested in...
FDA Claritin Hypospadia Review Targeted For Summer Completion
FDA's review of safety and birth registry data to determine whether Schering-Plough's Claritin (loratadine) could be linked to hypospadia is expected to take approximately three months
Claritin OTC Approval For CIU Would Reduce Off-Label Drug Use – Schering
Failure to approve Claritin OTC for chronic idiopathic urticaria would perpetuate off-label use of non-prescription drugs to treat hives, Schering-Plough told FDA's Nonprescription Drugs Advisory Committee at a meeting in Bethesda, Md. April 22
OTC Claritin Hatch/Waxman Exclusivity Not Expected By Schering-Plough
Schering-Plough does not expect to receive three years of Hatch/Waxman exclusivity for its supplemental NDAs for OTC Claritin (loratadine)